Featured News
LuGENE® Lupus Test Launches to Predict Flares & Drug Targets
AMPEL BioSolutions’ Precision Medicine Breakthrough Predicts Drug Options with RNA Analytics & Machine Learning
Virginia Workforce Award to AMPEL BioSolutions
AMPEL on Bloomberg Markets
Lupus, coronary artery disease share genetic risk factors; data may lead to early testing
Innovator-of-Year to AMPEL
COMPANY
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
PLATFORM
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
PRODUCTS
Now, A Simple Blood Test Can Identify Patients At Risk Of Severe COVID-19
Will I get severe ill if infected with COVID-19? This new genomic test can identify patients at high risk for poor outcomes.
AMPEL BioSolutions Enters MDx Market With Lupus, Dermatology Gene Expression Assays
After nine years in business, precision medicine company AMPEL BioSolutions is broadening its market from pharmaceutical companies to healthcare providers and their patients.
Virginia Based AMPEL BioSolutions’ Machine Learning Breakthrough Predicts Chronic Disease Flares From A Blood Sample
CLICK FOR ORIGINAL ARTICLE > AMPEL BioSolutions announces a breakthrough in precision and personalized medicine that could revolutionize the way doctors treat chronic diseases, like Lupus. CHARLOTTESVILLE, Va., July 9, 2019 /PRNewswire/ -- AMPEL BioSolutions today...
AMPEL BioSolutions’ Machine Learning Breakthrough Predicts Drug Options for Inflammatory Skin Diseases
AMPEL BioSolutions announced a breakthrough in precision and personalized medicine that could revolutionize the way doctors treat inflammatory skin diseases, such as Lupus, Psoriasis, Atopic Dermatitis and Scleroderma.
Ready for Prime Time? Ampel’s Blood Tests May Predict Drug Options for Inflammatory Skin Disease
Products expected to launch in 2022-2023 include LuGENE, a blood test for Lupus, and DermaGENE a skin biopsy test for lupus, psoriasis, atopic dermatitis, and scleroderma.
New test may guide treatment of common skin diseases
Dermatologists routinely do skin biopsies to figure out what’s wrong with their patients. They study tissue under a microscope – looking at the structure of cells, but a Charlottesville company says doctors could treat disease more precisely by looking at genetics.
PARTNERS
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.